These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 33412229)
1. Insights into kinetics, release, and behavioral effects of brain-targeted hybrid nanoparticles for cholesterol delivery in Huntington's disease. Birolini G; Valenza M; Ottonelli I; Passoni A; Favagrossa M; Duskey JT; Bombaci M; Vandelli MA; Colombo L; Bagnati R; Caccia C; Leoni V; Taroni F; Forni F; Ruozi B; Salmona M; Tosi G; Cattaneo E J Control Release; 2021 Feb; 330():587-598. PubMed ID: 33412229 [TBL] [Abstract][Full Text] [Related]
2. Chronic cholesterol administration to the brain supports complete and long-lasting cognitive and motor amelioration in Huntington's disease. Birolini G; Valenza M; Ottonelli I; Talpo F; Minoli L; Cappelleri A; Bombaci M; Caccia C; Canevari C; Trucco A; Leoni V; Passoni A; Favagrossa M; Nucera MR; Colombo L; Paltrinieri S; Bagnati R; Duskey JT; Caraffi R; Vandelli MA; Taroni F; Salmona M; Scanziani E; Biella G; Ruozi B; Tosi G; Cattaneo E Pharmacol Res; 2023 Aug; 194():106823. PubMed ID: 37336430 [TBL] [Abstract][Full Text] [Related]
3. Cholesterol-loaded nanoparticles ameliorate synaptic and cognitive function in Huntington's disease mice. Valenza M; Chen JY; Di Paolo E; Ruozi B; Belletti D; Ferrari Bardile C; Leoni V; Caccia C; Brilli E; Di Donato S; Boido MM; Vercelli A; Vandelli MA; Forni F; Cepeda C; Levine MS; Tosi G; Cattaneo E EMBO Mol Med; 2015 Dec; 7(12):1547-64. PubMed ID: 26589247 [TBL] [Abstract][Full Text] [Related]
4. Hybrid nanoparticles as a new technological approach to enhance the delivery of cholesterol into the brain. Belletti D; Grabrucker AM; Pederzoli F; Menrath I; Vandelli MA; Tosi G; Duskey TJ; Forni F; Ruozi B Int J Pharm; 2018 May; 543(1-2):300-310. PubMed ID: 29608954 [TBL] [Abstract][Full Text] [Related]
5. Striatal infusion of cholesterol promotes dose-dependent behavioral benefits and exerts disease-modifying effects in Huntington's disease mice. Birolini G; Valenza M; Di Paolo E; Vezzoli E; Talpo F; Maniezzi C; Caccia C; Leoni V; Taroni F; Bocchi VD; Conforti P; Sogne E; Petricca L; Cariulo C; Verani M; Caricasole A; Falqui A; Biella G; Cattaneo E EMBO Mol Med; 2020 Oct; 12(10):e12519. PubMed ID: 32959531 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of Cholesterol Nose-to-Brain Delivery for Brain Targeting in Huntington's Disease. Passoni A; Favagrossa M; Colombo L; Bagnati R; Gobbi M; Diomede L; Birolini G; Di Paolo E; Valenza M; Cattaneo E; Salmona M ACS Chem Neurosci; 2020 Feb; 11(3):367-372. PubMed ID: 31860272 [TBL] [Abstract][Full Text] [Related]
7. Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier. Tosi G; Fano RA; Bondioli L; Badiali L; Benassi R; Rivasi F; Ruozi B; Forni F; Vandelli MA Nanomedicine (Lond); 2011 Apr; 6(3):423-36. PubMed ID: 21542682 [TBL] [Abstract][Full Text] [Related]
8. Biodegradable Nanoparticles Containing Mechanism Based Peptide Inhibitors Reduce Polyglutamine Aggregation in Cell Models and Alleviate Motor Symptoms in a Drosophila Model of Huntington's Disease. Joshi AS; Singh V; Gahane A; Thakur AK ACS Chem Neurosci; 2019 Mar; 10(3):1603-1614. PubMed ID: 30452227 [TBL] [Abstract][Full Text] [Related]
9. Potential use of polymeric nanoparticles for drug delivery across the blood-brain barrier. Tosi G; Bortot B; Ruozi B; Dolcetta D; Vandelli MA; Forni F; Severini GM Curr Med Chem; 2013; 20(17):2212-25. PubMed ID: 23458620 [TBL] [Abstract][Full Text] [Related]
10. Selenium Nanoparticles as an Efficient Nanomedicine for the Therapy of Huntington's Disease. Cong W; Bai R; Li YF; Wang L; Chen C ACS Appl Mater Interfaces; 2019 Sep; 11(38):34725-34735. PubMed ID: 31479233 [TBL] [Abstract][Full Text] [Related]
11. Nanotechnology in Improving the Treatment of Huntington's Disease: a Systematic Review. Valadão KMG; Luizeti BO; Yamaguchi MU; Issy AC; Bernuci MP Neurotox Res; 2022 Apr; 40(2):636-645. PubMed ID: 35060083 [TBL] [Abstract][Full Text] [Related]
12. Biodegradable delivery system containing a peptide inhibitor of polyglutamine aggregation: a step toward therapeutic development in Huntington's disease. Joshi AS; Thakur AK J Pept Sci; 2014 Aug; 20(8):630-9. PubMed ID: 24788406 [TBL] [Abstract][Full Text] [Related]
13. Exploiting Bacterial Pathways for BBB Crossing with PLGA Nanoparticles Modified with a Mutated Form of Diphtheria Toxin (CRM197): In Vivo Experiments. Tosi G; Vilella A; Veratti P; Belletti D; Pederzoli F; Ruozi B; Vandelli MA; Zoli M; Forni F Mol Pharm; 2015 Oct; 12(10):3672-84. PubMed ID: 26312414 [TBL] [Abstract][Full Text] [Related]
14. Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys. Cho IK; Yang B; Forest C; Qian L; Chan AWS PLoS One; 2019; 14(3):e0214156. PubMed ID: 30897183 [TBL] [Abstract][Full Text] [Related]
15. Brain Cholesterol Synthesis and Metabolism is Progressively Disturbed in the R6/1 Mouse Model of Huntington's Disease: A Targeted GC-MS/MS Sterol Analysis. Kreilaus F; Spiro AS; Hannan AJ; Garner B; Jenner AM J Huntingtons Dis; 2015; 4(4):305-18. PubMed ID: 26639223 [TBL] [Abstract][Full Text] [Related]
16. Insight on the fate of CNS-targeted nanoparticles. Part I: Rab5-dependent cell-specific uptake and distribution. Vilella A; Tosi G; Grabrucker AM; Ruozi B; Belletti D; Vandelli MA; Boeckers TM; Forni F; Zoli M J Control Release; 2014 Jan; 174():195-201. PubMed ID: 24316476 [TBL] [Abstract][Full Text] [Related]